Press Coverage, Opinion Arda Ozcubukcu 22/06/2023 Press Coverage, Opinion Arda Ozcubukcu 22/06/2023 Will the UK’s ambitious life sciences investment power-up the psychedelic sector? Read More Press Coverage, Opinion Arda Ozcubukcu 03/04/2023 Press Coverage, Opinion Arda Ozcubukcu 03/04/2023 Why Reinvent the Wheel When You Can Amplify the Effects of Existing Therapy Models? Read More Opinion Arda Ozcubukcu 09/01/2023 Opinion Arda Ozcubukcu 09/01/2023 Transatlantic Psychedelics: drug developers without borders Read More Opinion Arda Ozcubukcu 21/11/2022 Opinion Arda Ozcubukcu 21/11/2022 The Weakest Link: Poor quality therapists a risk to psychedelic trial success Read More Opinion Arda Ozcubukcu 27/10/2022 Opinion Arda Ozcubukcu 27/10/2022 Regulatory approval in under 8 weeks possible for psychedelic trials in the UK Read More Opinion Arda Ozcubukcu 29/09/2022 Opinion Arda Ozcubukcu 29/09/2022 Rising tides lift all ships: What attracts drug developers to the UK’s psychedelic ecosystem? Read More Opinion Arda Ozcubukcu 14/07/2022 Opinion Arda Ozcubukcu 14/07/2022 The Race for Data Exclusivity Read More Opinion Clerkenwell Press Office 21/06/2022 Opinion Clerkenwell Press Office 21/06/2022 How It Works: ‘Setting’ Read More Opinion Arda Ozcubukcu 31/03/2022 Opinion Arda Ozcubukcu 31/03/2022 Thou Shalt Not Pass: Solving the Psychedelic Specialist Therapist Bottleneck Read More Opinion Arda Ozcubukcu 09/03/2022 Opinion Arda Ozcubukcu 09/03/2022 The Gold Standard for Psychedelic-Assisted Therapy? Read More Opinion Arda Ozcubukcu 22/11/2021 Opinion Arda Ozcubukcu 22/11/2021 Is the UK an ideal location to run psychedelic trials? Read More Opinion Arda Ozcubukcu 21/09/2021 Opinion Arda Ozcubukcu 21/09/2021 Why Psychedelic Drugs Need Specialist Clinical Research Organisations? Read More Opinion Arda Ozcubukcu 04/06/2021 Opinion Arda Ozcubukcu 04/06/2021 The psychedelic industry needs data. But what data, and why? Read More
Press Coverage, Opinion Arda Ozcubukcu 22/06/2023 Press Coverage, Opinion Arda Ozcubukcu 22/06/2023 Will the UK’s ambitious life sciences investment power-up the psychedelic sector? Read More
Press Coverage, Opinion Arda Ozcubukcu 03/04/2023 Press Coverage, Opinion Arda Ozcubukcu 03/04/2023 Why Reinvent the Wheel When You Can Amplify the Effects of Existing Therapy Models? Read More
Opinion Arda Ozcubukcu 09/01/2023 Opinion Arda Ozcubukcu 09/01/2023 Transatlantic Psychedelics: drug developers without borders Read More
Opinion Arda Ozcubukcu 21/11/2022 Opinion Arda Ozcubukcu 21/11/2022 The Weakest Link: Poor quality therapists a risk to psychedelic trial success Read More
Opinion Arda Ozcubukcu 27/10/2022 Opinion Arda Ozcubukcu 27/10/2022 Regulatory approval in under 8 weeks possible for psychedelic trials in the UK Read More
Opinion Arda Ozcubukcu 29/09/2022 Opinion Arda Ozcubukcu 29/09/2022 Rising tides lift all ships: What attracts drug developers to the UK’s psychedelic ecosystem? Read More
Opinion Arda Ozcubukcu 14/07/2022 Opinion Arda Ozcubukcu 14/07/2022 The Race for Data Exclusivity Read More
Opinion Clerkenwell Press Office 21/06/2022 Opinion Clerkenwell Press Office 21/06/2022 How It Works: ‘Setting’ Read More
Opinion Arda Ozcubukcu 31/03/2022 Opinion Arda Ozcubukcu 31/03/2022 Thou Shalt Not Pass: Solving the Psychedelic Specialist Therapist Bottleneck Read More
Opinion Arda Ozcubukcu 09/03/2022 Opinion Arda Ozcubukcu 09/03/2022 The Gold Standard for Psychedelic-Assisted Therapy? Read More
Opinion Arda Ozcubukcu 22/11/2021 Opinion Arda Ozcubukcu 22/11/2021 Is the UK an ideal location to run psychedelic trials? Read More
Opinion Arda Ozcubukcu 21/09/2021 Opinion Arda Ozcubukcu 21/09/2021 Why Psychedelic Drugs Need Specialist Clinical Research Organisations? Read More
Opinion Arda Ozcubukcu 04/06/2021 Opinion Arda Ozcubukcu 04/06/2021 The psychedelic industry needs data. But what data, and why? Read More